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a skilled nursing facility (SNF) (1.3[5.4] v 0.9[5.3]; p0.044) was longer on average for
DIS patients. DIS patients had higher ER AD-related costs compared to CON pa-
tients ($135[680] v $53[343] p0.011). CONCLUSIONS: Significantly less AD-related
health care utilization and costs were associated with continued D23 use compared
to patients who discontinued. More patients who continued therapy had 60 days
on donepezil 10mg before starting the D23 treatment vs DIS patients, suggesting
patients receive  60 days of 10 mg prior to initiating D23.
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OBJECTIVES: To evaluate the management of Spanish patients with multiple scle-
rosis (MS), to assess the unmet needs at the hospital pharmacy and the treatment
adherence fulfilled by MS patients treated with disease-modifying therapies (DMT).
METHODS: Non-interventional and multicenter study that recruited 237 patients
with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) treated
with DMT. Pharmacists completed a questionnaire on management actions and
unmet needs. Adherence was assessed using an adaptation of the Morisky-Green
test. RESULTS: Mean age of patients was 40.19.4 years (65.8% women). Average
time from diagnosis was 7.55.6 years, 95.4% RRMS, 61.2% with no relapses during
last year. Most patients presented EDSS grade 0-2.5 (62.4%). Overall patient adher-
ence was 77.1%. Treatment adherence was significantly higher among patients
with no relapses (82.9% vs 67.4%, p0.05) and among those 40 years (85.1% vs
68.3%, p0.05). 21.1% of pharmacists do not have adequate educational materials
and in 16% of cases there was no adequate space to assure confidentiality. Specific
protocol to monitor adverse events exists only in 21% of pharmacies and to monitor
adherence in 32%. Pharmacists emphasized as major unmet needs: educational
material, adherence training, staff and workload. According to main needs, there
was a trend towards lower adherence at hospitals with higher workload (68.6% vs
80.2%; p0.167) and with lack of educational materials (75.2% vs 84.6%; p0.435).
There were no adherence differences depending on the existence of available
space for training (76.9% vs 78.6%; p0.890) or between gender (84.1% men vs. 73.6%
women; p0.195). In 2 out of 10 cases (19.8%), a discrepancy exists between phar-
macist perception on adherence and Morisky-Green evaluation. CONCLUSIONS:
An improvement of educational materials and operational protocols regarding
workload is a requirement at hospital pharmacies to provide adequate follow-up
and to ensure adherence by MS patients in Spain.
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OBJECTIVES: To assess the health-related quality of life (HRQoL) of young onset
Parkinson’s Disease (PD) people. METHODS: An online survey (2011) of PD people
65 years at diagnosis included demographics, disease management and the As-
sessment of Quality of Life (AQoL). AQoL utility score was calculated where 1.00
represented full and 0.00 death equivalent HRQoL. Disease severity was classified
by Hoehn & Yahr Stages (H&Y). RESULTS: There were 254 participants. Mean diag-
nosis age was 50 years (SD 9); mean time since diagnosis was 6 years. PD was mild
for most participants (n  115, 65, 46, 11 and 4 for H&Y 1 to 5 respectively). The
mean AQoL utility was 0.54 (SD  0.26), which was below the 50-59 years popula-
tion norm (0.80, SD 0.24). HRQoL deterioration was monotonic by H&Y level: 0.67
for Level 1, 0.55 Level 2, 0.36 Level 3 and 0.10 (Levels 4/5). For those aged 20-39 years
at diagnosis the mean AQoL score was 0.41; for 40-49 years 0.50; for 50-59 years 0.58;
and for 60 years it was 0.68 (p0.01). Regarding time since diagnosis, for those
with recent diagnosis (0-2 years) the mean AQoL score was 0.61; 0.63 for those
diagnosed 3-5 years previously; 0.50 for those diagnosed 6-10 years previously; and
0.35 for those diagnosed 11 years previously (p0.01). AQoL scores varied by
gender (females’ mean AQoL 0.59, males’ 0.51, p0.01) and labourforce partic-
ipation (working  0.64, not working  0.39, not in the labourforce  0.50, p0.01).
There were no significant differences by age or relationship. Multivariate analysis
revealed, after adjustment, the significant predictors of AQoL scores were H&Y
classification (p0.01) and diagnosis age (p0.02). CONCLUSIONS:HRQoL of young
onset patients deteriorates as PD progresses. Further research is needed to see if
this can be ameliorated through interventions.
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OBJECTIVES: To describe health state values (utilities) in Alzheimer’s disease (AD)
patients and their caregivers by disease severity. METHODS: GERAS is a prospec-
tive, multi-centre, non-interventional cohort study in France, Germany and the UK,
enrolment October 2010-October 2011. Patients presenting within the normal
course of care who were55 years, diagnosed with probable AD (NINCDS-ADRDA),
not institutionalised and with an informal caregiver were categorised according to
MMSE score as mild (26-21), moderate (20-15) or severe (14 or less) AD. Caregivers
completed the EQ-5D to assess their own health-related quality of life and as prox-
ies for the patient. The UK population-based tariff was used to produce health state
values ranging from 1 (perfect health) to 0 (dead). RESULTS: The study cohort
included 1497 AD patients (38% mild, 32% moderate and 31% severe AD) and their
caregivers (n419 France, n552 Germany and n526 UK) with a mean (SD) patient
age of 77.6 (7.7) years (77.3 mild; 77.8 moderate; 77.6 severe) and 55% female (48%
mild; 57% moderate; 61% severe; p0.001). Caregivers had a mean (SD) age of 67.3
(12.0) years, 64% female and 66% of caregivers were the spouse of the AD patient.
Patient mean (SD) health state values differed significantly based on MMSE cate-
gorisation; mild 0.71 (0.24), moderate 0.64 (0.27) and severe 0.51 (0.34); (p0.001).
Health state values did not statistically differ between caregivers based on MMSE
categorisation [mean (SD) scores for mild 0.82 (0.20), moderate 0.81 (0.21) and se-
vere 0.79 (0.26); p0.069]. CONCLUSIONS: Health state values from the GERAS
study differentiate in AD patients based on MMSE severity, although are higher
than expected. Caregiver values do not statistically separate using the same cate-
gorisation. Health state values from this large cohort of European patients provide
new data for economic evaluation of AD treatments.
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OBJECTIVES:Advances in the management and care of patients with cystic fibrosis
(CF) has led to the majority of patients surviving into adulthood. Whether this
longevity has added quality years to the lives of CF patients is a question which
needs to be addressed. The aim of quality of life (QoL) measurement in CF should be
to quantify and evaluate the impact of both the disease and its treatments on the
wider aspects of the patient’s life. Pilot study was conducted to determine utility
indexes in children with CF using russian version of health utility index question-
naire (HUI).METHODS: Forty-five CF children 6-17 years with moderate and severe
forms of CF interviewed using HUI questionnaire version 15Q, while children over
12 years responded on their own (self assessment), information about children
under 12 years was obtained from parents (proxy assessment) .Version translated
into russian language and has been adapted. Questionnaire designed to assess QoL
and to determine the indexes used in the future indicator for calculating quality
adjusted life years. QoL assessment was carried out on systems HUI 2 and 3. Single-
attribute utility scores and multi-attribute utility scores evaluated corresponding
to each system, ranges from 0 to 1. RESULTS: Single-attribute utility scores index
HUI 3: Vision – 1, Hearing - 1; Speech - 0.96; Cognition - 0.93, Ambulation - 0.98,
Dexterity- 0.98, Emotions-0.96;Pain–0.94. Single-attribute utility scores index HUI
2: Sensation - 0.93; Mobility - 0.99; Cognition - 0.93; Self-care - 0.94; Emotion - 0.92;
Pain - 0.95. In patients with severe and moderate form of CF significant difference
of utility indexes was revealed in Ambulation (g0,011), Pain (g0,008), Mobility
(g0,011) and Emotions (p0.024). CONCLUSIONS: Russian version of HUI ques-
tionnaire showed its accessibility and results can be used in scientific, clinical and
economic studies to assess QoL in children. Ambulation, pain and emotion have
more influence on health status in CF children.
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OBJECTIVES: To evaluate the effect of dalfampridine extended release (D-ER; sus-
tained-, modified-, prolonged-release fampridine outside the US) on utility scores
in multiple sclerosis (MS) patients, estimated using two equations mapping the
12-item MS Walking Scale (MSWS-12) individual item scores to the Euroqol 5-Di-
mension (EQ-5D).METHODS:Data from MS-F203, a randomized trial of D-ER, 10mg
twice daily in MS patients, were used to calculate utility scores with two equations
mapping MSWS-12 item scores to the EQ-5D (one derived in a North American [NA]
registry, the other a United Kingdom [UK] registry). MS-F203 participants were
categorized as D-ER responders (a priori definition of consistent improvement on
the Timed 25-Foot Walk), D-ER nonresponders, or placebo. Mean change in utility
from baseline to each double-blind treatment evaluation (visits 3-6 occurring at
post-randomization weeks 2, 6, 10, 14) and each off-drug follow-up evaluation
(visits 7-8 occurring at weeks 16, 18) were calculated as effect sizes (ESs). RESULTS:
Using the NA-derived equation, D-ER responders demonstrated improvement in
utility vs. placebo or D-ER nonresponders, respectively; starting at week 6 (mean
difference in ES0.37, p0.01; ES0.40, p0.01) and maintained at weeks 10
(ES0.26, p0.17; ES0.31, p0.03) and 14 (ES0.48, p0.01; ES0.34, p0.04). Im-
provements were not apparent after D-ER discontinuation (p0.05 at weeks 16 and
18). Using the UK-derived equation, improvement was seen in D-ER responders vs.
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placebo or D-ER nonresponders, respectively, at weeks 6 (ES0.55, p0.01; ES0.76,
p0.01), 10 (ES0.48, p0.04; ES0.55, p0.01), and 14 (ES0.77, p0.01; ES0.67,
p0.01). No improvement was seen after D-ER discontinuation at weeks 16 and 18
(p0.05 for both). D-ER nonresponders did not show improvement vs. placebo at
any visit using either equation. CONCLUSIONS: Regardless of the mapping equa-
tion used, D-ER response was associated with an improvement in utility. The UK-
derived equation resulted in larger estimates of improvement than the NA-derived
equation.
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OBJECTIVES: Although information is available on how adults with epilepsy value
their quality-of-life (QoL), there are no published data regarding the short-term
impact of seizures on children or adults. Furthermore, utility studies in epilepsy
have concentrated on examining the impact of different seizure frequencies on
patients’ QoL rather than the impact of seizures themselves. Given that adminis-
tration of questionnaires during (or shortly after) a seizure is impossible and un-
ethical, alternative methods are required. As part of the BUCCOLAM® (oromusocal
midazolam) submission to the AWMSG, an exploratory analysis was conducted to
determine the short-term impact of seizures on QoL.METHODS: Four UK clinicians
were asked to qualitatively describe the impact of seizure on children and parents/
carers, to estimate utility values during and shortly after a seizure using the EQ-
5D-5L questionnaire, and to assess how long it takes children to recover from
seizures of different severities. RESULTS: Clinicians described the utility of pa-
tients during seizure as equivalent to death (not capable of experiencing or doing
anything), and the parents’/carers’ quality of life being significantly reduced (low-
est level on anxiety/depression scale). Using the EQ-5D-5L, the baseline utility of a
normal healthy child with epilepsy was estimated at 0.92. This decreased to -0.334
during seizure, 0.722 immediately following seizure (for a short seizure with no
ambulance required) and 0.1 for a more severe seizure (where an ambulance was
required). The mean prolonged acute seizure duration in children was estimated at
5–20 minutes, with time to full recovery estimated as 24 hours for a seizure not
leading to hospital admission, and 3-5 days for a seizure requiring hospitalisation.
CONCLUSIONS: Seizures appear to have a major impact on the QoL of both children
and their parents/carers. Although short-term in nature, seizures are also associ-
ated with disproportionate recovery times, with a resulting impact on QoL.
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OBJECTIVES:The Huntington Clinical Self-Reported Instrument (H-CSRI) is the first
subjective clinimetric scale for patients with Huntington’s disease (HD). Such an
instrument offers the advantage of allowing a remote follow-up, and collection of
information on the development of motor, functional and behavioural symptoms
of HD, perceived by the patients themselves. The objective of this study was to
adapt and cross-culturally validate the H-CSRI for Spain. METHODS: The original
questionnaire included three subscales assessing patients’ motor ability (13 Likert-
type items in four dimensions), functional capacity (seven Yes/No questions) and
behavioural ability (13 Likert-type items in four dimensions). The instrument was
translated forwards and backwards by native speakers. The hospital ‘Hospital Ramon
y Cajal’ provided their patients with the questionnaire. Classical test theory and
item response theory were used to assess its clinimetric properties. Cross-cultural
validation was assessed by differential item functioning analysis (DIF). RESULTS:A
total of 59 patients filled in the H-CSRI questionnaire. The H-CSRI showed satisfac-
tory psychometric proprieties. Item response rates ranged from 84% to 94%. A floor
effect was found for five items in the behavioural dimension. The H-CSRI showed
an acceptable reliability, as Cronbach’s alpha coefficients were higher than 0.85.
Factor analyses demonstrated that the data were structured in the same way as for
the French and the Italian versions. Item internal consistency (IIC) and item dis-
criminant validity criteria were met for most items (i.e. IIC was  0.40, and corre-
lations between items and their respective rest-scores in one dimension were all
greater than correlations with another dimension). The DIF analyses showed no
item bias versus the Italian or French versions. CONCLUSIONS: The Spanish ver-
sion of the H-CSRI showed acceptable clinimetric properties. This study supports
the usefulness of the H-CSRI questionnaire to assess the clinical status of patients,
although it is limited by the small sample size.
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OBJECTIVES: To assess the frequency, severity, use of hypnotics and impact of
sleep problems in the community in the UK. METHODS: Questionnaires were in-
serted in a national newspaper and patients with sleep problems requested to
complete them and return by post. RESULTS: Two thousand and eighty-two ques-
tionnaires were returned. Within the questionnaires returned not all of the ques-
tions were answered with some questions being more frequently completed than
others. We report the outcome for individually completed questions. Sixty-four
percent of respondents were female, 92% aged forty or over and 57% over 60; 94% of
patients reported insomnia for more than a year. Seventy-seven percent described
sleep as bad or very bad. 64% complained of feeling tired after rising and starting
the next day. Only 3% thought they got off to sleep in less than 20 minutes with 55%
reporting taking greater than 1 hour to get to sleep. A total of 86% visited the doctor
less than 4 times per year but apparently did not complain of insomnia; 44% re-
ported having received hypnotics from the doctor in the past but only 2% currently
taking them. Seven percent of patients attributed their sleep problems to pain; 42%
of patients get up regularly to use the bathroom but in general did not attribute
their sleep problems to this reason. In contrast 40% of respondents felt that their
problems were purely age-related. CONCLUSIONS: Insomnia is a common, long-
standing, serious problem which afflicts and impacts upon older rather than
younger people. While most respondents had received hypnotics in the past they
were not currently taking them despite continuing to suffer from insomnia. There
appears a common acceptance that sleep problems are simply a function of ageing.
This study demonstrates the need for patient education and for physicians to
address the problem of insomnia in older age.
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OBJECTIVES: Spasticity and fatigue are common in patients with Multiple Sclerosis
(MS) and can highly affect patients’ quality-of-life (QoL). A burden-of-disease study
was performed to gain real-life data on MS-related fatigue and the patients’ and
physicians’ evaluation of fatigue and QoL. METHODS: The MOVE 1 (MObility Im-
proVEment) study included a cross-sectional investigation of fatigue and QoL of MS
spasticity patients, using the “Würzburger Erschöpfungsinventar bei Multipler
Sklerose” (WEIMuS, German MS-related fatigue questionnaire) and the EQ-5D QoL
instrument. WEIMuS total score (0-68; cut-off 32), cognitive (0–36; cut-off 17)
and physical (0–32; cut-off 16) fatigue subscores are obtained. EQ-5D includes 5
domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depres-
sion) with 3 answer levels (no, some and extreme problems). RESULTS: In total, 419
MS patients with spasticity were enrolled at 42 German centres from 4/2011 to
9/2011. 414 patients fulfilled selection criteria and were analyzed. Mean age was
48.6 ( 9.6) y., 64.3% were female. According to physicians, 27.3% of patients had
mild, 44.0% moderate and 28.7% severe spasticity. Fatigue was recorded by physi-
cians in 49.4% and by patients in 50.0% of cases as one of the most disturbing
spasticity associated symptoms. According to WEIMuS, total fatigue cut-off score
was reached by 48.0%, 53.8% and 54.5% of patients with mild, moderate or severe
spasticity; while physical fatigue was observed in 52.9%, 69.6% and 66.3% and cog-
nitive fatigue in 37.3%, 35.7% and 37.6% of these subgroups, respectively. With
increasing spasticity severity the mean EQ-5D index value decreased (0.60.2 to
0.30.3) and the number of patients with “extreme problems” raised, particularly
in the domains “mobility” (0% to 13.6%), “self-care” (1.0% to 20.0%) and “usual
activity” (2.9% to 25.5%). CONCLUSIONS: The occurrence of fatigue in MS patients
increases with spasticity severity, impairing patients’ QoL in parallel. Patients’ and
physicians’ evaluations are aligned.
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OBJECTIVES: The psychometric properties of the Multiple Sclerosis Impact Scale
(MSIS-29) have been well examined in community-based samples using cross-
sectional data, but not yet in trial-based samples using longitudinal data. This
analysis examined MSIS-29’s validity and responsiveness using longitudinal data
from patients with relapsing-remitting multiple sclerosis (RRMS) enrolled in the
SELECT trial of daclizumab HYP. METHODS: The MSIS-29 and EQ-5D tariff and
visual analogue scale (VAS) were administered at baseline, 3, 6, and 12 months to
600 patients with RRMS who had mean age of 35.8 (SD8.91) years and Expanded
Disability Status Scale of 2.7 (SD1.17) at baseline. The convergent and discrimi-
nant validity of MSIS-29 was assessed by examining the strength of correlations
between the physical and psychological scores of the MSIS-29 and each of the five
EQ-5D dimensions at all time points. MSIS-29 responsiveness was evaluated by
examining the direction, magnitude, and pattern of change in MSIS-29 scores in
three patient subgroups defined by achieving an established minimal important
EQ-5D VAS change of 5.5 points at each time point from baseline (improved 5.5,
-5.5  stable 5.5, worsened -5.5). RESULTS: As expected, the MSIS-29 physical
scale was more highly correlated with the EQ-5D dimensions usual activities
(r0.66) and mobility (r0.62) and least correlated with anxiety/depression
(r0.48). Conversely, the psychological scale was more highly correlated with the
EQ-5D anxiety/depression (r0.64) and least correlated with personal care (r0.35)
and mobility (r0.42). The direction, magnitude, and pattern of change in the phys-
ical and psychological scores over time in each subgroup were consistent with
expectations, showing insignificant change among stable patients, but significant
change among those who improved or worsened. CONCLUSIONS: The MSIS-29 is a
valid and responsive measure among trial-based subjects. This analysis supports
its use as a disease-specific measure of treatment effect on the physical and psy-
chological well-being of MS patients.
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